A Phase 3 interventional study of Salbutamol and Beclomethasone dipropionate + Formoterol in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 206 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.
Among the 40 studies testing beclomethasone in Asthma, this one has the largest enrollment, is one of 2 that started in 2009, is one of 20 in phase 3, and was the 12th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →
Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 22 · Phase 4 9
First in 1995; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,714 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 67 across the 40 interventional studies. Of the 35 that completed or were terminated, 14 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 40 have an industry lead sponsor. The 10 most frequent:
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
81 studies in Asthma by Chiesi Farmaceutici S.p.A.: 11 open now, 11 under way, 2 of them phase 3. Of 69 finished, 13 (19%) have results posted.
Among the 81 studies in Asthma by Chiesi Farmaceutici S.p.A., this one has the largest enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2009, is one of 24 in phase 3, and was the 12th registered.
Chiesi Farmaceutici S.p.A.’s Asthma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing beclomethasone in Asthma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chiesi Farmaceutici S.p.A.’s 81 in Asthma:
This tab as a report to print or save as PDF → With an account.
Primary objective:
The primary objective of the study was to compare the efficacy of Maintenance and Reliever Therapy (MART) with Foster® 100/6 μg (one inhalation bid) plus additional inhalations as needed, with the standard treatment of Foster® 100/6 μg (one inhalation bid) plus salbutamol 100 μg (Ventolin ®) additional inhalations as needed in not fully controlled asthmatic patients.
Secondary objectives:
The secondary objectives of the study were:
This was a 48-week phase III, double-blind, randomized, 2-arm parallel group study in asthmatic patients (adults of both sexes) not fully controlled under ICS treatment.
The study plan included:
A) Foster® 100/6 μg one inhalation bid for maintenance plus additional inhalations as needed; B) Foster® 100/6 μg one inhalation bid for maintenance plus salbutamol as needed.
The total study duration per participant was 50 weeks, including the 2-week run-in period, 48-week treatment phase.
Salbutamol was used as a rescue medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free combination with long acting β2 agonists (LABA) at a constant dose (changes in doses for less than seven days were accepted) for two months before V1.
Not fully controlled asthmatics (which means partly controlled or/and uncontrolled patients according to GINA guidelines 2007) (apart from asthma exacerbation criteria) in the last month before V1.
Asthma control was assessed in terms of:
Partly controlled patients were those with at least one of the above mentioned symptoms/signs in any week of the last month before V1.
Uncontrolled patients were those with 3 or more features of partly controlled asthma present in any week of the last month before V1.
Not fully controlled asthma (defined according to criterion No. 7) in the last week of the run-in was to be confirmed at Visit 2.
Exclusion Criteria:
Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotrophin laboratory test (> 5 mIU/mL). Women of , defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means, unless they met the following definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or were using one or more of the following acceptable methods of :
Acceptable methods of contraception could include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensured compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal were not acceptable methods of contraception. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one inhalation of Foster (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose) administered via a pMDI, BID, as maintenance therapy and additional inhalations of Foster (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose) as needed in response to symptoms as reliever therapy. A maximum of 6 inhalations per day was allowed as reliever therapy. To ensure blinding, participants received inhalations of placebo matching Ventolin as reliever therapy. Participants received treatment for a duration of 48 weeks.
Drug: Beclomethasone dipropionate + Formoterol
Participants received one inhalation of Foster (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose) administered via a pMDI, BID, as maintenance therapy and additional inhalations of Ventolin (Salbutamol, 100 μg per metered dose) as needed in response to symptoms as reliever therapy. A maximum of 6 inhalations per day was allowed as reliever therapy. To ensure blinding, participants received inhalations of placebo matching Foster as reliever therapy. Participants received treatment for a duration of 48 weeks.
Drug: Salbutamol · Drug: Beclomethasone dipropionate + Formoterol
Administered via a pressurized metered-dose inhaler
Also known as: Ventolin
Drug pages: Beclomethasone · Formoterol
Administered via a pressurized metered-dose inhaler
Also known as: Foster
Time to First Severe Asthma Exacerbation
A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. Since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, the median time of first exacerbation is not available (N.A.). So, to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period was reported separately.
Time frame: From First IMP dose to week 48 (EOT)
Cumulative Number of Patients With Severe Asthma Exacerbation by Inter-visit (Measured in Weeks)
A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. As already anticipated in the primary endpoint, since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, and the median time of first exacerbation is not available (N.A.), to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period is here reported.
Time frame: From First dose to end of each interval: 0-4, 4-12, 12-24, 24-36, 36-48 weeks
Number of Severe Asthma Exacerbations Per 100 Patients Per Year
A severe asthma exacerbation was defined as asthma worsening, resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days. As per the outcome measure title, the total number of severe exacerbations (this outcome), of hospitalisations/emergency room treatment, of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms. Please note that in case of two close severe asthma exacerbations (start date of a severe asthma exacerbation is less than 10 days from the stop date of the previous severe asthma exacerbation), only the first was counted for the analysis.
Time frame: First dose to end of the study (Up to 48 Weeks)
Number of Systemic Corticosteroids Courses to Treat Asthma Per 100 Patients Per Year
Systemic corticosteroids courses to treat asthma started at or after the first dose of randomised study drug and with at least one day from the stop date of a systemic corticosteroids course and the start date of the following one have been considered for analysis. As per the outcome measure title, the total number of severe exacerbations (other outcome), of hospitalisations/emergency room treatment (other outcome), of systemic corticosteroids use (this outcome) is expressed as rate (events per 100 patients per year) and compared between arms.
Time frame: First dose to end of the study (Up to 48 Weeks)
Number of Hospitalisation/Emergency Room Treatments Due to Asthma Per 100 Patients Per Year
Hospitalization or emergency room treatment due to asthma started at or after the first dose of randomised study drug was be considered for the analysis. As per the outcome measure title, the total number of severe exacerbations (another outcome), of hospitalisations/emergency room treatment (this outcome), of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms.
Time frame: From first dose to end of the study (Up to Week 48)
Change From Baseline in Asthma Control Questionnaire (ACQ) Score to Each Visit
The Asthma Control Questionnaire is a tool used to asses how well a participant asthma is controlled and consists of seven questions scored. On average/in general, during the past week 0 (no impairment), 6 (maximum impairment for symptoms). 1. how often were you woken by your asthma during the night? 2. how bad were your asthma symptoms when you woke up in the morning? 3. how limited were you in your activities because of your asthma? 4. how much shortness of breath did you experience because of your asthma? 5. how much of the time did you wheeze? 6. how many puffs/inhalations of short-acting bronchodilator have you used each day? 7. FEV1 pre-bronchodilator, FEV1 predicted FEV1 % predicted (by clinical staff) The ACQ total score has been calculated as the mean of the seven question scores ranging from 0 (totally controlled) and 6 (severely uncontrolled). Higher scores indicate the worse outcomes. Adjusted means were reported.
Time frame: Week 4 (V3), Week 12 (V4), Week 24 (V5), Week 36 (V6), Week 48 (V7)
Number of Mild Asthma Exacerbations Per 100 Patients / Year
A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. As per the outcome measure title, the total number of mild asthma exacerbations is expressed as rate (events per 100 patients per year) and compared between arms.
Time frame: From first dose through end of the study (Up to Week 48)
Number of Mild Asthma Exacerbations: Number of Total Events
A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Total number of mild asthma exacerbation events were reported. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. .
Time frame: From first dose through end of the study (Up to Week 48)
Time to First Mild Asthma Exacerbation
A "mild asthma exacerbation" was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only 1 mild exacerbation was considered. In case of two close mild exacerbations (start date of a mild exacerbation is less than 7 days from the stop date of the previous mild exacerbation), only the first was counted for the analysis. First mild exacerbation occurred after the first dose of randomised study drug and within end of study is considered for the analysis. In patient with at least one mild exacerbation, the time to first mild exacerbation was calculated as the time in days between the first dose of randomised study drug (derived) and the time at which the first mild exacerbation occurs (date of the first day of the first mild exacerbation). Time to first mild asthma exacerbation (days) = (date of first day of first mild exacerbation - date of first dose of randomised study drug (derived)) +1
Time frame: From first dose to end of the study (Up to Week 48)
Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) to Each Visit
PEF is measured twice a day (morning and evening) with Spirotel, a portable electronic peak flow meter. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant performed 3 blows and only the best PEF parameter was saved into the Spirotel memory.
Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Change From Baseline in Daily PEF Variability to Each Visit
PEF is measured twice a day (morning and evening) with Spirotel. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant will perform 3 blows and only the best PEF parameter will be saved into the Spirotel memory. The variability of PEF of a day will be calculated using the Best PEF morning and the Best PEF evening recorded in the same day. Variability of PEF is measured daily with Spirotel using the following formula: Best PEF evening - Best PEF morning/Best PEF evening + Best PEF morning/2 X 100
Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Each Visit
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry, conducted at baseline and all clinical visits. An increase in FEV1 reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEV1 values indicate better lung function. Adjusted means were reported.
Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Change From Baseline in Pre-Dose Forced Expiratory Flow Between 25% and 75% of Vital Capacity (FEF25-75%) at Each Visit
FEF is a lung function test and is measured using the spirometery. The FEF25%-75% is the forced expiratory flow from 25% to 75% of FVC. FEF25%-75% measurement is conducted at baseline and all clinical visits. An increase in FEF25%-75% reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEF25%-75% values indicate better lung function. Adjusted means were reported.
Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Change From Baseline in Total Asthma Symptom Scores Measured Daily by Each Visit
The asthma symptoms are: cough, wheeze, chest tightness and breathlessness. Each morning and evening asthma symptoms are to be scored, as respectively occurred during the night and during the day, as follows: Night-time asthma symptom score: 0 = No symptom, 1 = Mild: symptoms not causing awakening, 2 = Moderate: discomfort enough to cause awakening, 3 = Severe: causing awakening for most of the night / do not allow to sleep at all Day-time asthma symptom score: 0 = No symptom, 1 = Mild: aware of symptoms which can be easily tolerated, 2 = Moderate: discomfort enough to cause interference with daily activity, 3 = Severe: incapacitating with inability to work / take part in usual activity Total asthma symptoms score was calculated as the sum of the day-time and the night-time asthma symptoms score recorded on the following day and score ranges from 0 to 6, higher score indicates worse symptoms.
Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Number of Inhalations of Reliever Medication Per Day by Each Two-Week Period
The daily use of reliever medication was calculated as sum of the number of puffs taken during the day and the number of puffs taken during the night recorded on the following day. In case one session in a day is missing, only the available session (evening or morning) was considered for the daily use of reliever medication. A minimum of seven evaluable measurements are required in each two-week treatment period and during the two-weeks of the run-in period (baseline).
Time frame: Weeks 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18,19-20,21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48
Percentage of Asthma Symptom-free Days by Each Two-Week Period
Asthma symptom-free days are days with the total asthma symptom score equal to zero. Percentage of asthma symptom-free days will be calculated in each two-week period using the following formula: % of asthma symptoms- free days = Number o f asthma symptoms- free days in that two - week period/Number o f days with data recorded for asthma symptom scores in that two - week period X 100.
Time frame: Week 3-4, 11-12, 23-24, 35-36 and 47-48
Percentage of Reliever-Medication-Free Days by Each Two-Week Period
A day without reliever medication is a day in which the number of puffs of reliever medication taken in the 24 hours is zero. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not-free" if one session is recorded and the other is missing. Percentage of reliever medication-free days will be calculated in each two-week period using the following formula: % of reliever medication-free days = Number of reliever medication-free days in that two -week period/Number of days with data recorded for reliever medication in that two -week period X 100
Time frame: Weeks 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18,19-20,21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48
Percentage of Asthma Control Days by Each Two-week Period Before Clinic Visits
Asthma control day is a day with total asthma symptom score equal to zero and without use of reliever medication. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not control" if one session is recorded and the other is missing. Percentage of asthma control days will be calculated in each two-week period using the following formula: % of asthma control days = Number of asthma control days in that two -week period/Number of days with data recorded for asthma symptom scores and reliever medication in that two-week period X100
Time frame: Week 3-4, 11-12, 23-24, 35-36 and 47-48
Number of Participants With Treatment Emergent Adverse Events
AE=An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. Serious AE= An adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. ADR=A response to a medicinal product which is harmful and unintended. Response in this context means that a causal relationship between the medicinal product and an adverse event is at least a reasonable possibility Serious ADR=An adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. Severe AE= "Severe" refers to the intensity of an AE; the event itself may be of relatively minor medical significance but intense.
Time frame: From first dose of study drug until end of the study (up to 48 weeks)
Number of Patients Who Required > 6 Rescue Inhalations Per Day for at Least Two Consecutive Days During During Treatment Period
Use of reliever medication was derived from the data of SpirotelTM. The event "more than six reliever medications per day for two consecutive days" is defined as at least two consecutive days with more than six puffs of reliever medication in the day.
Time frame: From first dose of study drug until end of the study (up to 48 weeks)
Participants were enrolled across 183 centers in 14 countries. A total of 2079 participants were screened for eligibility, 365 participants were screen failure and 1714 of them were enrolled and randomised in this study.
| Milestone | Foster (Treatment A) | Foster + Ventolin (Treatment B) |
|---|---|---|
| Started | 857 | 857 |
| Randomized population | 857 | 857 |
| Safety population | 854 | 854 |
| Intent-to-treat population | 852 | 849 |
| Completed | 758 | 748 |
| Not completed | 99 | 109 |
| Withdrew: Adverse event | 10 | 18 |
| Withdrew: Lack of therapeutic response | 2 | 5 |
| Withdrew: Lost to follow-up | 10 | 8 |
| Withdrew: Protocol violation | 31 | 27 |
| Withdrew: Poor compliance to study drug | 13 | 11 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Withdrawal by subject | 28 | 34 |
| Withdrew: Miscellaneous | 4 | 4 |
A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. Since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, the median time of first exacerbation is not available (N.A.). So, to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period was reported separately.
| weeks | Treatment A | Treatment B |
|---|---|---|
| Time to First Severe Asthma Exacerbation | NA (NA to NA) | NA (NA to NA) |
A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. As already anticipated in the primary endpoint, since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, and the median time of first exacerbation is not available (N.A.), to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period is here reported.
| no. of patients with exacerbation | Treatment A | Treatment B |
|---|---|---|
| weeks 0-4 | 11 | 18 |
| weeks 4-12 | 32 | 56 |
| weeks 12-24 | 70 | 103 |
| weeks 24-26 | 90 | 132 |
| weeks 36-48 (EoT) | 99 | 152 |
A severe asthma exacerbation was defined as asthma worsening, resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days. As per the outcome measure title, the total number of severe exacerbations (this outcome), of hospitalisations/emergency room treatment, of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms. Please note that in case of two close severe asthma exacerbations (start date of a severe asthma exacerbation is less than 10 days from the stop date of the previous severe asthma exacerbation), only the first was counted for the analysis.
| events per 100 patients per year | Treatment A | Treatment B |
|---|---|---|
| Number of Severe Asthma Exacerbations Per 100 Patients Per Year | 17.61 | 26.77 |
Systemic corticosteroids courses to treat asthma started at or after the first dose of randomised study drug and with at least one day from the stop date of a systemic corticosteroids course and the start date of the following one have been considered for analysis. As per the outcome measure title, the total number of severe exacerbations (other outcome), of hospitalisations/emergency room treatment (other outcome), of systemic corticosteroids use (this outcome) is expressed as rate (events per 100 patients per year) and compared between arms.
| Courses per 100 patients per year | Treatment A | Treatment B |
|---|---|---|
| Number of Systemic Corticosteroids Courses to Treat Asthma Per 100 Patients Per Year | 16.93 | 25.95 |
Hospitalization or emergency room treatment due to asthma started at or after the first dose of randomised study drug was be considered for the analysis. As per the outcome measure title, the total number of severe exacerbations (another outcome), of hospitalisations/emergency room treatment (this outcome), of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms.
| events x 100 patients x year | Treatment A | Treatment B |
|---|---|---|
| Number of Hospitalisation/Emergency Room Treatments Due to Asthma Per 100 Patients Per Year | 9.08 | 13.52 |
The Asthma Control Questionnaire is a tool used to asses how well a participant asthma is controlled and consists of seven questions scored. On average/in general, during the past week 0 (no impairment), 6 (maximum impairment for symptoms). 1. how often were you woken by your asthma during the night? 2. how bad were your asthma symptoms when you woke up in the morning? 3. how limited were you in your activities because of your asthma? 4. how much shortness of breath did you experience because of your asthma? 5. how much of the time did you wheeze? 6. how many puffs/inhalations of short-acting bronchodilator have you used each day? 7. FEV1 pre-bronchodilator, FEV1 predicted FEV1 % predicted (by clinical staff) The ACQ total score has been calculated as the mean of the seven question scores ranging from 0 (totally controlled) and 6 (severely uncontrolled). Higher scores indicate the worse outcomes. Adjusted means were reported.
| score on a scale | Treatment A | Treatment B |
|---|---|---|
| Week 4 (Visit 3) | -0.217 (-0.263 to -0.170) | -0.198 (-0.244 to -0.151) |
| Week 12 (Visit 4) | -0.289 (-0.340 to -0.238) | -0.258 (-0.309 to -0.207) |
| Week 24 (Visit 5) | -0.328 (-0.382 to -0.273) | -0.325 (-0.380 to -0.271) |
| Week 36 (Visit 6) | -0.410 (-0.466 to -0.354) | -0.373 (-0.429 to -0.317) |
| Week 48 (Visit 7) | -0.480 (-0.536 to -0.423) | -0.423 (-0.480 to -0.367) |
A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. As per the outcome measure title, the total number of mild asthma exacerbations is expressed as rate (events per 100 patients per year) and compared between arms.
| events per 100 patients per year | Treatment A | Treatment B |
|---|---|---|
| Number of Mild Asthma Exacerbations Per 100 Patients / Year | 385.65 | 380.99 |
A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Total number of mild asthma exacerbation events were reported. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. .
| Number of Events | Treatment A | Treatment B |
|---|---|---|
| Number of Mild Asthma Exacerbations: Number of Total Events | 2847 | 2789 |
A "mild asthma exacerbation" was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only 1 mild exacerbation was considered. In case of two close mild exacerbations (start date of a mild exacerbation is less than 7 days from the stop date of the previous mild exacerbation), only the first was counted for the analysis. First mild exacerbation occurred after the first dose of randomised study drug and within end of study is considered for the analysis. In patient with at least one mild exacerbation, the time to first mild exacerbation was calculated as the time in days between the first dose of randomised study drug (derived) and the time at which the first mild exacerbation occurs (date of the first day of the first mild exacerbation). Time to first mild asthma exacerbation (days) = (date of first day of first mild exacerbation - date of first dose of randomised study drug (derived)) +1
| weeks | Treatment A | Treatment B |
|---|---|---|
| Time to First Mild Asthma Exacerbation | 11.43 (9.43 to 12.9) | 9.57 (7.86 to 11.3) |
PEF is measured twice a day (morning and evening) with Spirotel, a portable electronic peak flow meter. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant performed 3 blows and only the best PEF parameter was saved into the Spirotel memory.
| Liters per minute | Treatment A | Treatment B |
|---|---|---|
| Morning PEF: Week 4 (Visit 3) | 2.40 ± 41.2 | -3.53 ± 37.3 |
| Morning PEF: week 12 (Visit 4) | -0.16 ± 45.8 | -11.5 ± 43.7 |
| Morning PEF: week 24 (Visit 5) | -4.01 ± 52.9 | -13.8 ± 46.1 |
| Morning PEF: Week 36 (Visit 6) | -5.83 ± 54.6 | -8.71 ± 54.1 |
| Morning PEF: Week 48 (Visit 7) | -7.48 ± 54.4 | -9.70 ± 52.7 |
| Evening PEF: Week 4 (Visit 3) | 0.69 ± 40.6 | -4.32 ± 36.9 |
| Evening PEF: Week 12 (Visit 4) | -2.54 ± 45.4 | -12.4 ± 42.3 |
| Evening PEF: week 24 (Visit 5) | -7.36 ± 48.8 | -15.2 ± 47.7 |
| Evening PEF: week 36 (Visit 6) | -7.20 ± 54.4 | -14.7 ± 51.4 |
| Evening PEF: week 48 (Visit 7) | -10.7 ± 57.2 | -16.8 ± 52.6 |
PEF is measured twice a day (morning and evening) with Spirotel. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant will perform 3 blows and only the best PEF parameter will be saved into the Spirotel memory. The variability of PEF of a day will be calculated using the Best PEF morning and the Best PEF evening recorded in the same day. Variability of PEF is measured daily with Spirotel using the following formula: Best PEF evening - Best PEF morning/Best PEF evening + Best PEF morning/2 X 100
| Liters per minute | Treatment A | Treatment B |
|---|---|---|
| Weeks 4 (Visit 3) | -0.29 ± 4.61 | 0.21 ± 5.08 |
| Weeks 12 (Visit 4) | -0.36 ± 4.93 | -0.38 ± 5.54 |
| Weeks 24 (Visit 5) | -0.49 ± 5.12 | -0.044 ± 6.21 |
| Weeks 36 (Visit 6) | -0.42 ± 5.21 | -0.24 ± 6.05 |
| Weeks 48 (Visit 7) | -0.017 ± 5.06 | -0.88 ± 6.29 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry, conducted at baseline and all clinical visits. An increase in FEV1 reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEV1 values indicate better lung function. Adjusted means were reported.
| Litres | Treatment A | Treatment B |
|---|---|---|
| Week 4 (Visit 3) | 0.09 ± 0.34 | 0.08 ± 0.36 |
| Week 12(Visit 4) | 0.11 ± 0.36 | 0.09 ± 0.38 |
| Week 24 (Visit 5) | 0.11 ± 0.38 | 0.10 ± 0.42 |
| Week 36 (Visit 6) | 0.12 ± 0.39 | 0.11 ± 0.42 |
| Week 48 (Visit 7) | 0.11 ± 0.39 | 0.11 ± 0.43 |
FEF is a lung function test and is measured using the spirometery. The FEF25%-75% is the forced expiratory flow from 25% to 75% of FVC. FEF25%-75% measurement is conducted at baseline and all clinical visits. An increase in FEF25%-75% reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEF25%-75% values indicate better lung function. Adjusted means were reported.
| Liters per Second | Treatment A | Treatment B |
|---|---|---|
| Week 4 (Visit 3) | 0.09 ± 0.56 | 0.07 ± 0.57 |
| Week 12 (Visit 4) | 0.09 ± 0.58 | 0.07 ± 0.62 |
| Week 24 (Visit 5) | 0.07 ± 0.66 | 0.06 ± 0.63 |
| Week 36 (Visit 6) | 0.10 ± 0.70 | 0.07 ± 0.65 |
| Week 48 (Visit 7) | 0.06 ± 0.61 | 0.06 ± 0.68 |
The asthma symptoms are: cough, wheeze, chest tightness and breathlessness. Each morning and evening asthma symptoms are to be scored, as respectively occurred during the night and during the day, as follows: Night-time asthma symptom score: 0 = No symptom, 1 = Mild: symptoms not causing awakening, 2 = Moderate: discomfort enough to cause awakening, 3 = Severe: causing awakening for most of the night / do not allow to sleep at all Day-time asthma symptom score: 0 = No symptom, 1 = Mild: aware of symptoms which can be easily tolerated, 2 = Moderate: discomfort enough to cause interference with daily activity, 3 = Severe: incapacitating with inability to work / take part in usual activity Total asthma symptoms score was calculated as the sum of the day-time and the night-time asthma symptoms score recorded on the following day and score ranges from 0 to 6, higher score indicates worse symptoms.
| score on a scale | Treatment A | Treatment B |
|---|---|---|
| Week 4 (Visit 3) | -0.78 ± 3.20 | -0.70 ± 3.64 |
| Week 12 (Visit 4) | -1.14 ± 3.83 | -1.01 ± 4.28 |
| Week 24 (Visit 5) | -1.54 ± 4.06 | -1.17 ± 4.78 |
| Week 36 (Visit 6) | -1.61 ± 4.11 | -1.40 ± 4.78 |
| Week 48 (Visit 7) | -1.67 ± 4.19 | -1.67 ± 4.77 |
The daily use of reliever medication was calculated as sum of the number of puffs taken during the day and the number of puffs taken during the night recorded on the following day. In case one session in a day is missing, only the available session (evening or morning) was considered for the daily use of reliever medication. A minimum of seven evaluable measurements are required in each two-week treatment period and during the two-weeks of the run-in period (baseline).
| Inhalations per day | Treatment A | Treatment B |
|---|---|---|
| Week 1-2 | 1.00 ± 1.36 | 0.99 ± 1.39 |
| Week 3-4 | 1.00 ± 1.42 | 0.96 ± 1.45 |
| Week 5-6 | 0.96 ± 1.30 | 0.95 ± 1.39 |
| Week 7-8 | 0.97 ± 1.38 | 0.92 ± 1.36 |
| Week 9-10 | 0.95 ± 1.37 | 0.91 ± 1.44 |
| Week 11-12 | 0.94 ± 1.36 | 0.88 ± 1.39 |
| Week 13-14 | 0.93 ± 1.32 | 0.88 ± 1.37 |
| Week 15-16 | 0.94 ± 1.32 | 0.89 ± 1.41 |
| Week 17-18 | 0.90 ± 1.28 | 0.84 ± 1.34 |
| Week 19-20 | 0.90 ± 1.29 | 0.83 ± 1.33 |
| Week 21-22 | 0.91 ± 1.33 | 0.86 ± 1.35 |
| Week 23-24 | 0.90 ± 1.32 | 0.85 ± 1.33 |
| Week 25-26 | 0.85 ± 1.24 | 0.82 ± 1.31 |
| Week 27-28 | 0.85 ± 1.25 | 0.78 ± 1.27 |
| Week 29-30 | 0.84 ± 1.23 | 0.79 ± 1.31 |
| Week 31-32 | 0.84 ± 1.27 | 0.79 ± 1.30 |
| Week 33-34 | 0.82 ± 1.21 | 0.75 ± 1.28 |
| Week 35-36 | 0.78 ± 1.16 | 0.74 ± 1.24 |
| Week 37-38 | 0.77 ± 1.22 | 0.70 ± 1.16 |
| Week 39-40 | 0.79 ± 1.22 | 0.71 ± 1.21 |
| Week 41-42 | 0.76 ± 1.18 | 0.71 ± 1.18 |
| Week 43-44 | 0.79 ± 1.24 | 0.70 ± 1.17 |
| Week 45-46 | 0.77 ± 1.20 | 0.71 ± 1.20 |
| Week 47-48 | 0.75 ± 1.14 | 0.71 ± 1.21 |
Asthma symptom-free days are days with the total asthma symptom score equal to zero. Percentage of asthma symptom-free days will be calculated in each two-week period using the following formula: % of asthma symptoms- free days = Number o f asthma symptoms- free days in that two - week period/Number o f days with data recorded for asthma symptom scores in that two - week period X 100.
| percentage of days | Treatment A | Treatment B |
|---|---|---|
| Weeks 3-4 | 12.5 ± 25.4 | 14.4 ± 26.9 |
| Weeks 11-12 | 15.2 ± 28.6 | 16.1 ± 28.1 |
| Weeks 23-24 | 16.3 ± 29.0 | 19.2 ± 31.5 |
| Weeks 35-36 | 18.8 ± 31.2 | 20.7 ± 32.4 |
| Weeks 47-48 | 18.8 ± 30.4 | 20.3 ± 32.4 |
A day without reliever medication is a day in which the number of puffs of reliever medication taken in the 24 hours is zero. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not-free" if one session is recorded and the other is missing. Percentage of reliever medication-free days will be calculated in each two-week period using the following formula: % of reliever medication-free days = Number of reliever medication-free days in that two -week period/Number of days with data recorded for reliever medication in that two -week period X 100
| percentage of days | Treatment A | Treatment B |
|---|---|---|
| Week 1-2 | 50.5 ± 37.9 | 52.3 ± 37.6 |
| Week 3-4 | 49.3 ± 38.2 | 52.8 ± 37.5 |
| Week 5-6 | 49.2 ± 38.1 | 52.5 ± 36.5 |
| Week 7-8 | 49.2 ± 38.1 | 52.2 ± 37.6 |
| Week 9-10 | 48.8 ± 38.4 | 52.9 ± 37.1 |
| Week 11-12 | 48.5 ± 37.7 | 52.5 ± 36.7 |
| Week 13-14 | 49.2 ± 38.1 | 52.4 ± 36.7 |
| Week 15-16 | 48.0 ± 37.7 | 53.0 ± 37.2 |
| Week 17-18 | 48.4 ± 37.6 | 52.4 ± 37.2 |
| Week 19-20 | 48.3 ± 37.3 | 53.1 ± 36.7 |
| Week 21-22 | 48.7 ± 37.6 | 52.6 ± 36.7 |
| Week 23-24 | 47.5 ± 37.0 | 52.3 ± 36.4 |
| Week 25-26 | 49.1 ± 36.9 | 52.4 ± 36.8 |
| Week 27-28 | 48.7 ± 37.3 | 52.3 ± 36.9 |
| Week 29-30 | 48.9 ± 37.1 | 53.3 ± 36.9 |
| Week 31-32 | 48.4 ± 37.0 | 53.1 ± 37.6 |
| Week 33-34 | 49.2 ± 37.2 | 54.0 ± 37.5 |
| Week 35-36 | 49.3 ± 36.6 | 53.2 ± 36.4 |
| Week 37-38 | 50.9 ± 37.4 | 53.8 ± 36.7 |
| Week 39-40 | 49.6 ± 37.6 | 53.6 ± 37.1 |
| Week 41-42 | 49.8 ± 37.6 | 53.8 ± 36.6 |
| Week 43-44 | 49.8 ± 37.8 | 52.7 ± 36.3 |
| Week 45-46 | 50.2 ± 37.7 | 53.8 ± 36.8 |
| Week 47-48 | 48.5 ± 36.5 | 52.9 ± 35.4 |
Asthma control day is a day with total asthma symptom score equal to zero and without use of reliever medication. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not control" if one session is recorded and the other is missing. Percentage of asthma control days will be calculated in each two-week period using the following formula: % of asthma control days = Number of asthma control days in that two -week period/Number of days with data recorded for asthma symptom scores and reliever medication in that two-week period X100
| percentage of days | Treatment A | Treatment B |
|---|---|---|
| Weeks 3-4 | 11.6 ± 24.5 | 13.7 ± 26.4 |
| Weeks 11-12 | 14.2 ± 27.9 | 15.4 ± 27.5 |
| Weeks 23-24 | 15.4 ± 28.1 | 18.2 ± 30.7 |
| Weeks 35-36 | 17.8 ± 30.4 | 19.3 ± 31.3 |
| Weeks 47-48 | 17.7 ± 29.3 | 19.2 ± 31.6 |
AE=An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. Serious AE= An adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. ADR=A response to a medicinal product which is harmful and unintended. Response in this context means that a causal relationship between the medicinal product and an adverse event is at least a reasonable possibility Serious ADR=An adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. Severe AE= "Severe" refers to the intensity of an AE; the event itself may be of relatively minor medical significance but intense.
| Participants | Treatment A | Treatment B |
|---|---|---|
| Number of patients with TEAEs | 379 | 380 |
| Number of patients with ADRs | 38 | 19 |
| Number of patients with serious TEAEs | 32 | 41 |
| Number of patients with severe TEAEs | 56 | 79 |
| Number of patients with TEAEs leading to death | 1 | 2 |
| Number of patients with TEAEs leading to withdrawal | 10 | 21 |
Use of reliever medication was derived from the data of SpirotelTM. The event "more than six reliever medications per day for two consecutive days" is defined as at least two consecutive days with more than six puffs of reliever medication in the day.
| Participants | Treatment A | Treatment B |
|---|---|---|
| Number of Patients Who Required > 6 Rescue Inhalations Per Day for at Least Two Consecutive Days During During Treatment Period | 59 | 70 |
Collected over From first dose of study drug to end of the study (Up to 48 Weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 1/854 (0.1%) | 32/854 (3.7%) | 370/854 (43.3%) |
| Treatment B | 2/854 (0.2%) | 41/854 (4.8%) | 360/854 (42.2%) |
| Event | Treatment A | Treatment B |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 8/854 | 19/854 |
| PneumoniaInfections and infestations | 3/854 | 2/854 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/854 | 2/854 |
| Angina pectorisCardiac disorders | 1/854 | 1/854 |
| Atrial fibrillationCardiac disorders | 0/854 | 1/854 |
| Cardiopulmonary failureCardiac disorders | 0/854 | 1/854 |
| Myocardial infarctionCardiac disorders | 1/854 | 1/854 |
| Duodenal ulcerGastrointestinal disorders | 1/854 | 0/854 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/854 | 0/854 |
| HaemorrhoidsGastrointestinal disorders | 0/854 | 1/854 |
| Event | Treatment A | Treatment B |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 103/854 | 158/854 |
| NasopharyngitisInfections and infestations | 74/854 | 72/854 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 25/854 | 31/854 |
| HeadacheNervous system disorders | 28/854 | 18/854 |
| BronchitisInfections and infestations | 26/854 | 19/854 |
| InfluenzaInfections and infestations | 7/854 | 17/854 |
| RhinitisInvestigations | 16/854 | 7/854 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/854 | 13/854 |
| HypertensionVascular disorders | 16/854 | 14/854 |
| PharyngitisInfections and infestations | 13/854 | 15/854 |
Intention-to-treat population (ITT), defined as all randomized patients who took at least one dose of study medication and with at least one available evaluation of efficacy after the baseline.
| Age, Continuous(Years) | Foster (Treatment A) | Foster + Ventolin (Treatment B) | Total |
|---|---|---|---|
| Mean | 48.9 ± 14.2 | 46.6 ± 13.8 | 47.8 ± 14.1 |
| Sex: Female, Male(Participants) | Foster (Treatment A) | Foster + Ventolin (Treatment B) | Total |
|---|---|---|---|
| Female | 521 | 528 | 1049 |
| Male | 331 | 321 | 652 |
| Race (NIH/OMB)(Participants) | Foster (Treatment A) | Foster + Ventolin (Treatment B) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 835 | 827 | 1662 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 16 | 18 | 34 |
| Region of Enrollment(participants) | Foster (Treatment A) | Foster + Ventolin (Treatment B) | Total |
|---|---|---|---|
| Bulgaria | 96 | 94 | 190 |
| Croatia | 22 | 22 | 44 |
| Czechia | 41 | 41 | 82 |
| France | 26 | 24 | 50 |
| Germany | 35 | 39 | 74 |
| Italy | 46 | 44 | 90 |
| Poland | 256 | 257 | 513 |
| Romania | 46 | 47 | 93 |
| Russia | 120 | 119 | 239 |
| Serbia | 45 | 44 | 89 |
| Spain | 1 | 0 | 1 |
| Turkey | 30 | 30 | 60 |
| Ukraine | 88 | 87 | 175 |
| United Kingdom | 0 | 1 | 1 |
Showing the first 100 of 206 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Mar 2009 to primary completion in Dec 2010, 20 months.
Results were first posted in May 2026, 15 years 5 months after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 20 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Beclomethasone · Formoterol